Janjigian, Y. Y., Moehler, M. H., Ajani, J. A., Shen, L., Garrido, M., Gallardo, C., Wyrwicz, L., Yamaguchi, K., Cleary, J. M., Elimova, E., Bruges, R. E., Karamouzis, M., Skoczylas, T., Bragagnoli, A., Liu, T., Tehfe, M., McCraith, S., Hu, N., Zhang, J., Shitara, K. (2025). Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 5-year (y) follow-up results from CheckMate 649.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.4_suppl.398